Financial Data and Key Metrics Changes - The company has a strong balance sheet with $17 million in cash, providing a runway of approximately 2.5 years, which is considered ample in the current industry context [6][9][13] - Historical cash burn averages between $5 million and $7 million per year, indicating a capital-efficient business model [8][15] Business Line Data and Key Metrics Changes - The company is advancing two lead clinical programs: a breast cancer vaccine and an ovarian cancer CAR T therapy, both currently in Phase 1 clinical trials with promising clinical data [3][16] - The breast cancer vaccine is funded by a U.S. Government grant, which helps keep cash burn low [17][34] Market Data and Key Metrics Changes - The breast cancer market is large and well-known, while the ovarian cancer market, though smaller, presents a significant unmet medical need with poor outcomes [5] - The company is targeting both neoadjuvant and primary prevention markets for its breast cancer vaccine, indicating a broad market strategy [40] Company Strategy and Development Direction - The company leverages partnerships with top-tier academic institutions like Moffitt Cancer Center and Cleveland Clinic to enhance its research capabilities without incurring high costs [4][10] - The strategy focuses on advancing clinical programs through early stages and partnering with pharmaceutical companies for later-stage development and commercialization [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical data being generated, particularly regarding the safety and efficacy of the ovarian cancer CAR T therapy, with encouraging survival rates observed in treated patients [27][28] - The company aims to present final data from the Phase 1 trial of the breast cancer vaccine at the San Antonio Breast Cancer Symposium in December, indicating a proactive approach to sharing results [39] Other Important Information - The company has maintained consistent insider buying over the years, reflecting management's confidence in the business [7] - There are no outstanding warrants, preferred stock, or debt, which positions the company favorably for future financing [13] Q&A Session Summary Question: What is the current status of the ovarian cancer CAR T therapy? - The therapy is in Phase 1 trials, with encouraging safety profiles and overall survival rates observed in treated patients [27][28] Question: How is the breast cancer vaccine funded? - The breast cancer vaccine is fully funded by a U.S. Government grant, which helps minimize cash burn [17][34] Question: What are the next steps for the breast cancer vaccine program? - The company plans to present final data from the Phase 1 trial at the San Antonio Breast Cancer Symposium in December and is preparing for a Phase 2 trial [39][40]

These cases suggest biological activity and support continued dose escalation for ovarian cancer patients who have no alternatives. We expect to report further clinical observations later this year. Our partnership with Moffitt—a leader in cellular immunotherapy—continues to be a vital asset in developing this novel technology. SAN JOSE, Calif., May 19, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of c ...

Forward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such ...

Group 1 - Anixa Biosciences, Inc. is participating in the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at Nasdaq World Headquarters in New York City [1][2] - Mike Catelani, President and CFO of Anixa, will present and be available for one-on-one meetings during the conference [1][2] - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [2] Group 2 - The company's vaccine portfolio includes vaccines for breast and ovarian cancer developed in collaboration with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [2] - Anixa's business model involves partnerships with renowned research institutions at all stages of development, allowing for the exploration of emerging technologies for further development and commercialization [2]

Core Viewpoint - Anixa Biosciences (ANIX) shares rose by 13% following the announcement of a new patent for its breast cancer vaccine technology, developed in collaboration with Cleveland Clinic, which is currently in early-stage studies [1][4]. Group 1: Patent and Technology - The new patent broadens the immunogenic compositions for Anixa's breast cancer vaccine, focusing on the human α-lactalbumin protein, which is present in breast tissue during lactation and expressed in certain breast cancers, making it a viable target for immunoprevention [2]. - The patent enhances Anixa's intellectual property portfolio, emphasizing the uniqueness of its investigational breast cancer vaccine, thereby strengthening the company's competitive position [4]. Group 2: Clinical Trials and Future Plans - The ongoing phase I study is assessing the breast cancer vaccine's maximum tolerated dose and immune response in patients with early-stage, triple-negative breast cancer, showing antigen-specific immune responses and a favorable safety profile [5]. - Based on positive findings, Anixa plans to initiate a phase II study in 2025 to evaluate the vaccine's therapeutic effect in a pre-surgery setting for breast cancer [5]. Group 3: Collaborations and Other Developments - Anixa is collaborating with Cleveland Clinic on additional vaccines targeting ovarian, lung, colon, and prostate cancers, which are currently in pre-clinical or discovery stages [7]. - The innovative vaccine technologies have a unique mechanism of action, potentially offering therapeutic benefits over existing treatments, with Cleveland Clinic entitled to royalties from their development [8]. - Anixa is also developing an immunotherapy candidate for ovarian cancer in partnership with Moffitt Cancer Center, currently in a phase I study [9].

Core Points - Anixa Biosciences has received a Notice of Allowance for a new patent related to its breast cancer vaccine technology, which broadens the scope of immunogenic compositions used in the vaccine [1][2] - The patent covers methods of immunizing patients against breast cancer using an immunogenic composition containing the human α-lactalbumin protein, which is expressed in certain breast cancers [2] - The CEO of Anixa highlighted that this patent enhances the company's intellectual property portfolio, which includes multiple issued and pending patents in the U.S. and internationally [3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [3] - The company's vaccine portfolio includes vaccines for breast and ovarian cancer, as well as other cancer vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [3] - Anixa's business model involves partnerships with renowned research institutions, allowing the company to explore emerging technologies for further development and commercialization [3]

Core Viewpoint - Anixa Biosciences, Inc. is participating in the Jones Las Vegas Healthcare and Technology Innovation Conference, highlighting its focus on cancer treatment and prevention [1][2]. Group 1: Conference Details - The conference will take place on April 8-9, 2025, at The Venetian Resort in Las Vegas, Nevada [1]. - Mike Catelani, President and CFO of Anixa, will present on April 9, 2025, at 4:30 PM PT and will be available for one-on-one meetings [2]. - The event aims to facilitate direct dialogue between innovative companies and institutional investors through various formats including presentations and networking events [2]. Group 2: Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4]. - The company is also developing vaccines in partnership with Cleveland Clinic to treat and prevent breast and ovarian cancers, as well as other vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [4]. - Anixa's business model involves partnerships with renowned research institutions, allowing for continuous exploration of emerging technologies for development and commercialization [4].

Core Viewpoint - Anixa Biosciences has entered into a letter of intent with VERDI Solutions to develop personalized and off-the-shelf peptide vaccines for cancer patients, leveraging advanced technology and real-world data to enhance treatment accessibility and efficacy [1][5]. Group 1: Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes immunotherapy programs and various cancer vaccines developed in collaboration with renowned research institutions [8][9]. - VERDI Solutions, based in Vienna, Austria, is pioneering personalized cancer treatment by utilizing artificial intelligence and cloud computing to create tailored cancer vaccines, making them more accessible to patients [2]. Group 2: Technology and Innovation - VERDI's cloud-computing platform allows for rapid development of personalized peptide vaccines based on individual patient data, aiming to improve treatment outcomes through companion diagnostics [2][6]. - The company has successfully administered personalized vaccines to three patients with bone metastases, resulting in significant pain relief and improved quality of life, indicating the potential of its platform [4][6]. Group 3: Regulatory and Market Context - In some European countries, oncologists can prescribe personalized cancer vaccines under the Individueller Heilversuch, providing a pathway for broader patient access and valuable real-world efficacy data [3]. - The increasing recognition of real-world evidence by global regulatory agencies supports the development and commercialization of personalized cancer vaccines, positioning VERDI as a leader in this innovative approach [3]. Group 4: Strategic Collaboration - The letter of intent grants Anixa a six-month exclusive right to negotiate for the research, development, and commercialization of VERDI's cancer vaccines, aligning with Anixa's strategy for a capital-efficient business model in personalized cancer care [5][7].

SAN JOSE, Calif., March 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent application covering its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting Anti-Mullerian Hormone Receptor, Type II ( ...

Core Insights - Anixa Biosciences, Inc. is set to present at the 2025 Cancer Advocacy Group of Louisiana NeauxCancer Conference, highlighting its advancements in cancer treatment and prevention [1][2] - The presentation will focus on Anixa's CAR-T therapy for solid tumors and novel cancer vaccine initiatives, showcasing the company's progress in clinical development and next-generation immunotherapies [2] Company Overview - Anixa is a clinical-stage biotechnology company dedicated to cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company is also developing vaccines in partnership with Cleveland Clinic to treat and prevent breast and ovarian cancers, as well as other vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [4] - Anixa's business model involves collaboration with renowned research institutions throughout all stages of development, allowing for the exploration of emerging technologies for further development and commercialization [4]